- The introduction of new test kits for pharmacies will reduce the complexity of the current medical cannabis preparation process
- Materia has the exclusive right to sell the products through its existing national pharmacy network as well as to new pharmacy and wholesale customers
LONDON, May 5, 2021 / PRNewswire / – Materia, a European medical cannabis and wellness company, today announced that its wholly owned subsidiary Materia Deutschland GmbH (“Materia Deutschland”) has partnered with German diagnostics company Saxonia Diagnostics GmbH (“Saxonia Diagnostics”) for the exclusive distribution of its branded cannabis testing products throughout Germany.
These products, which are sold under the CannaFix-ID® brand, offer a highly efficient alternative to cannabis pharmacies, which, due to their status as a judicial preparation, are required for testing medical cannabis according to German regulations. The innovative technology is designed to ease the cumbersome process by which cannabis products are currently being tested Germany.
“The German DAB monograph requires pharmacies to test products using time-consuming, often expensive thin-layer chromatography or another comparable method. This is often an obstacle to widespread acceptance of medical cannabis in pharmacies. The CannaFix-ID® portfolio is an exciting alternative that is qualified as a comparable method. This makes testing for pharmacies much easier and more economical, “said Sebastian Blöte, Managing Director of Materia Germany. “We are pleased to be working with Saxonia, whose team has extensive pharmaceutical expertise, particularly in the medical cannabis space. Their vision of providing pharmacies with convenient and efficient solutions fits perfectly with our own.”
The first product made available under the partnership is a validated THC test kit that can be used on flowers, extracts and dronabinol. The second offers both THC and CBD tests for flowers and extracts. Both tests have been successfully validated on a bundle of different medical cannabis products.
“Comprehensive validation with a user-friendly approach is essential to overcome the barriers to wider medical cannabis dispensing,” he said Michael Pfeffer, Managing Director of Saxonia Diagnostics.
The products have been developed, validated and tested in Germany. The official launch of German pharmacies is planned May 2021.
Materia’s vision is to enable global access to cannabis. Materia is developing a resilient ecosystem for drug manufacturing and distribution to expand the legal cannabinoid market Europe. With its research-driven team and regulatory expertise, Materia focuses on the high margin downstream activities of processing, formulation and distribution in markets wherever a patient is in need of cannabis medicine or CBD consumers looking for innovative new products.
Saxonia Diagnostics was founded with a deep belief in radically simplifying the testing of medical cannabis by providing validated, world-class solutions for pharmacies. As an independent diagnostics company, Saxonia Diagnostics can offer solutions for all cannabis medicines available on the German market, such as flowers, extracts and dronabinol.
SOURCE Materia Ventures